{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:36:02Z","timestamp":1779888962160,"version":"3.53.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002635","name":"Inha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.transproceed.2019.04.078","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T17:19:28Z","timestamp":1563988768000},"page":"2689-2692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Ultra-Low-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in High-Risk Kidney Transplantation Patients"],"prefix":"10.1016","volume":"51","author":[{"given":"Jin Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Ryong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hun","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seun Deuk","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.transproceed.2019.04.078_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"issue":"Suppl. 4","key":"10.1016\/j.transproceed.2019.04.078_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.04.078_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician\u2019s update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2019.04.078_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2006.01.015","article-title":"The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection","volume":"36","author":"Reischig","year":"2006","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.transproceed.2019.04.078_bib5","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.transproceed.2016.05.004","article-title":"Extended low-dose valganciclovir is effective prophylaxis against cytomegalovirus in high-risk kidney transplant recipients with near-complete eradication of late-onset disease","volume":"48","author":"Fayek","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2019.04.078_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.04.078_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.transproceed.2019.04.078_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0041-1345(96)00301-6","article-title":"Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation","volume":"29","author":"Kaden","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2019.04.078_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/lt.20562","article-title":"Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients","volume":"12","author":"Park","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2019.04.078_bib10","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.transproceed.2018.04.010","article-title":"Efficacy of ultralow-dose valganciclovir chemoprophylaxis for cytomegalovirus infection in ABO-incompatible kidney transplantation recipients","volume":"50","author":"Lee","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2019.04.078_bib11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1086\/427506","article-title":"Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence","volume":"40","author":"Singh","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2019.04.078_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1702226","article-title":"Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection","volume":"25","author":"Einsele","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2019.04.078_bib13","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.04.078_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519302738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519302738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:32:52Z","timestamp":1758576772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519302738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0041134519302738"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.04.078","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ultra-Low-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in High-Risk Kidney Transplantation Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.04.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}